Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Lexicon Pharmaceuticals stock | 1.29

Own Lexicon Pharmaceuticals stock in just a few minutes.

Posted

Fact checked

Lexicon Pharmaceuticals, Inc is a biotechnology business based in the US. Lexicon Pharmaceuticals shares (LXRX) are listed on the NASDAQ and all prices are listed in US Dollars. Lexicon Pharmaceuticals employs 184 staff and has a trailing 12-month revenue of around USD$32.5 million.

How to buy shares in Lexicon Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Lexicon Pharmaceuticals. Find the stock by name or ticker symbol: LXRX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Lexicon Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$1.29, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Lexicon Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Lexicon Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Lexicon Pharmaceuticals's share price?

Since the stock market crash in March caused by coronavirus, Lexicon Pharmaceuticals's share price has had significant negative movement.

Its last market close was USD$1.29, which is 52.04% down on its pre-crash value of USD$2.69 and 31.78% down on the lowest point reached during the March crash when the shares fell as low as USD$1.7.

If you had bought USD$1,000 worth of Lexicon Pharmaceuticals shares at the start of February 2020, those shares would have been worth USD$664.49 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$420.19.

Lexicon Pharmaceuticals share price

Use our graph to track the performance of LXRX stocks over time.

Lexicon Pharmaceuticals shares at a glance

Information last updated 2020-11-19.
Latest market close USD$1.29
52-week range USD$1.03 - USD$5.33
50-day moving average USD$1.3469
200-day moving average USD$1.7238
Wall St. target price USD$2.37
PE ratio 3.7419
Dividend yield N/A (0%)
Earnings per share (TTM) USD$0.369

Buy Lexicon Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Lexicon Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Lexicon Pharmaceuticals price performance over time

Historical closes compared with the close of $1.29 from 2020-11-16

1 week (2020-11-18) -19.38%
1 month (2020-10-26) -3.73%
3 months (2020-08-25) -28.33%
6 months (2020-05-22) -35.82%
1 year (2019-11-25) -65.46%
2 years (2018-11-23) -82.75%
3 years (2017-11-24) -86.77%
5 years (2015-11-25) -90.61%

Is Lexicon Pharmaceuticals under- or over-valued?

Valuing Lexicon Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Lexicon Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Lexicon Pharmaceuticals's P/E ratio

Lexicon Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 4x. In other words, Lexicon Pharmaceuticals shares trade at around 4x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Lexicon Pharmaceuticals's EBITDA

Lexicon Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$82.5 million.

The EBITDA is a measure of a Lexicon Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Lexicon Pharmaceuticals financials

Revenue TTM USD$32.5 million
Gross profit TTM USD$226.9 million
Return on assets TTM -42.76%
Return on equity TTM -82.6%
Profit margin 0%
Book value $0.753
Market capitalisation USD$182.1 million

TTM: trailing 12 months

Shorting Lexicon Pharmaceuticals shares

There are currently 9.7 million Lexicon Pharmaceuticals shares held short by investors – that's known as Lexicon Pharmaceuticals's "short interest". This figure is 3.1% up from 9.4 million last month.

There are a few different ways that this level of interest in shorting Lexicon Pharmaceuticals shares can be evaluated.

Lexicon Pharmaceuticals's "short interest ratio" (SIR)

Lexicon Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Lexicon Pharmaceuticals shares currently shorted divided by the average quantity of Lexicon Pharmaceuticals shares traded daily (recently around 819551.18443316). Lexicon Pharmaceuticals's SIR currently stands at 11.82. In other words for every 100,000 Lexicon Pharmaceuticals shares traded daily on the market, roughly 11820 shares are currently held short.

However Lexicon Pharmaceuticals's short interest can also be evaluated against the total number of Lexicon Pharmaceuticals shares, or, against the total number of tradable Lexicon Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Lexicon Pharmaceuticals's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Lexicon Pharmaceuticals shares in existence, roughly 80 shares are currently held short) or 0.2467% of the tradable shares (for every 100,000 tradable Lexicon Pharmaceuticals shares, roughly 247 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Lexicon Pharmaceuticals.

Find out more about how you can short Lexicon Pharmaceuticals stock.

Lexicon Pharmaceuticals share dividends

We're not expecting Lexicon Pharmaceuticals to pay a dividend over the next 12 months.

Have Lexicon Pharmaceuticals's shares ever split?

Lexicon Pharmaceuticals's shares were split on a 1:7 basis on 21 May 2015. So if you had owned 7 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Lexicon Pharmaceuticals shares – just the quantity. However, indirectly, the new 600% higher share price could have impacted the market appetite for Lexicon Pharmaceuticals shares which in turn could have impacted Lexicon Pharmaceuticals's share price.

Lexicon Pharmaceuticals share price volatility

Over the last 12 months, Lexicon Pharmaceuticals's shares have ranged in value from as little as $1.03 up to $5.33. A popular way to gauge a stock's volatility is its "beta".

LXRX.US volatility(beta: 1.62)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Lexicon Pharmaceuticals's is 1.6156. This would suggest that Lexicon Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Lexicon Pharmaceuticals overview

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the treatment of type 1 and is in Phase III clinical trials for the treatment of type 2 diabetes; LX9211, which is in Phase I clinical development for the treatment of neuropathic pain; and LX2761 that is in Phase I clinical development for the treatment of diabetes. The company has strategic collaboration and license agreements with Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site